Author

Amee J. George

Australian National UniversityORCID 0000-0002-0265-4476Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

Adrià ClosaiD· 2 shared Katherine M. HannaniD· 2 shared Luc FuriciD· 2 shared Nadine HeiniD· 2 shared Perlita PohiD· 2 shared Rita FerreiraiD· 2 shared Ross D. HannaniD· 2 shared Alisee HugloiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Adrià ClosaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Novel RNA Polymerase I and Cyclin Dependent Kinase combination therapy for the treatment of aggressive Acute Myeloid Leukemia.

Nadine Hein, Perlita Poh, Jason A. Powell, Lorena Núñez-Villacís, Sarah Sant’Anna Maranhão, Maurits Evers, Jirawas Sornkom, Victoria S. Pope, Priscilla Soo, Adrià Closa, Jasmina Frawley, Sheren J. Al-Obaidi, Cathryn M. Gould, Piyush B. Madhamshettiwar, Kaylene J. Simpson, , Rita Ferreira

This paper identifies a synergistic combination of RNA Polymerase I inhibitor CX-5461 and CDK inhibitor Dinaciclib that enhances therapeutic efficacy in AML by inducing nucleolar stress and cell cycle arrest.

Leukemia · Oct 8, 2026Peer-reviewedCancer Biology

The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high MYC malignancies.

Rita Ferreira, Katherine M. Hannan, Kostya I. Panov, Thejaani P. Udumanne, Amee J. George, Adrià Closa, Zaka Wing-Sze Yuen, Eduardo Eyras, Perlita Poh, Kylee H. Maclachlan, Mitchell Dwyer, Vanessa Barn, Jin-Shu He, Eric P. Kusnadi, Richard J. Rebello, , Nadine Hein

This study shows PMR-116, a second-generation RiBi inhibitor, effectively targets high-MYC cancers without causing DNA damage, suggesting RiBi as a viable cancer therapy.

bioRxiv · Apr 19, 2025 · PreprintCancer Biology